Drug Companies' Patent-Extending Strategies Substantially Increases Health Care Costs

Evergreening strategies--where pharmaceutical companies slightly change the formulation of their brand drug into "follow on" drugs by combining formulations or producing slow-release forms, for example, so that they can extend the patent--substantially contributed to an increase in overall healthcare costs in the Swiss canton of Geneva, according to a study by international researchers published in this week's PLOS Medicine...